). The median day at the maximum AEC was 61.5 days (range 28-99) after CBT. Moderate-to-severe eosinophilia occurred in 24 (23.8%) patients at a median of 40 days (range 27-98) after CBT. The median duration was 10 days (range . Severe eosinophilia occurred in four (4.0%) patients at a median of 48.5 days (range 41-56) after CBT. The median duration was 2.5 days (range [1] [2] [3] [4] . No study patients were treated for eosinophilia.
The association of possible risk factors for developing eosinophilia after CBT was studied using Fisher's exact test. Age (less than 40 versus 40 years or more), gender (male versus female), disease status (low risk versus high risk), total nucleated cell dose (less than 2.5 Â 10 7 versus 2.5 Â 10 7 /kg or more), CD34-positive cell dose (less than 1.0 Â 10 5 versus 1.0 Â 10 5 /kg or more) and HLA-matching (5-or 4-match versus 3-or 2-match) were not associated with the incidence of mild-to-severe or moderate-to-severe eosinophilia (data not shown). Unexpectedly, pretransplant CMV-seropositivity was associated with a lower incidence of moderate-to-severe eosinophilia after CBT (17.6 versus 56.2%, P ¼ 0.0004), but not mild-to-severe eosinophilia (72.9 versus 81.2%, P ¼ 0.10). The main reason for the association between pretransplant CMV seropositivity and less occurrence of moderate-to-severe eosinophilia after CBT is probably the myelotoxic effect of ganciclovir therapy against CMV infection. The association between GVHD and eosinophilia within 100 days after CBT was studied. Grade II-IV acute GVHD occurred in 47 of 75 (62.7%) patients with mild-to-severe eosinophilia and 14 of 26 (53.8%) patients without mildto-severe eosinophilia (P ¼ 0.44 by Fisher's exact test).
In patients with and without moderate-to-severe eosinophilia, grade II-IV acute GVHD occurred in 17 of 24 (70.8%) and 44 of 77 (56.1%), respectively (P ¼ 0.13). Within 1 year after CBT, chronic GVHD occurred in 65 of 75 (86.7%) patients with mild-to-severe eosinophilia and 24 of 26 (92.3%) patients without mild-to-severe eosinophilia (P ¼ 0.52). In patients with and without moderate-to-severe eosinophilia, chronic GVHD occurred in 20 of 24 (83.3%) and 69 of 77 (89.6%), respectively (P ¼ 0.49). These results indicate no association between eosinophilia and acute or chronic GVHD after CBT.
The impact of eosinophilia within 100 days after CBT on disease-free survival (DFS) was studied using the KaplanMeier method and the log-rank test. The probabilities of DFS at 3 years after CBT in patients with and without eosinophilia were 81.5 and 82.6%, respectively (P ¼ 0.96). In patients with and without moderate-to-severe eosinophilia, DFS also did not differ significantly (87.1 versus 80.8%, P ¼ 0.76). These results indicate no association between eosinophilia and DFS after CBT.
This study showed that eosinophilia (AEC 4500 Â 10 6 /l) occurred in 75 of 101 (74.3%) patients within 100 days after CBT. This incidence seems to be higher than the previously reported incidence of eosinophilia ranging from 9.4 to 38.9%. [4] [5] [6] Aisa et al. 7 showed that the incidence of eosinophilia, defined as blood eosinophil percentage of more than 4%, was 57% at 100 days after SCT. When we used this definition to diagnose eosinophilia, the incidence at 100 days after CBT increased to 93.1% in our study patients. Because of differences in various conditions other than the stem cell source, such as the conditioning regimen and GVHD prophylaxis, the precise comparison of the incidence in our report and in others is difficult; however, our study shows that eosinophilia is quite common after CBT.
The association between eosinophilia and GVHD remains controversial. In previous studies, some authors suggested that eosinophilia after SCT is clinically correlated with the development of acute or chronic GVHD. 5, 6, [8] [9] [10] In contrast, Aisa et al. 7 recently showed that eosinophilia (blood eosinophil 44%) within 100 days after SCT was associated with lower rates of grade II-IV acute GVHD (43 versus 68%, Po0.001) and chronic GVHD (60 versus 74%, P ¼ 0.011). As eosinophilia can occur in Th-2-mediated processes, the authors speculate that the association between eosinophilia and the reduced incidence of severe acute GVHD may reflect the immunosuppressive role of Th-2 cytokines.
Sato et al. 4 showed that pediatric patients with eosinophilia (AEC 4500 Â 10 6 /l) at any time after SCT had a higher event-free survival rate (81.1 versus 44.6%, P ¼ 0.0025). As eosinophilia was also associated with a lower relapse rate (16.0 versus 43.0%, P ¼ 0.0287), the authors speculate the involvement of a GVL effect. Aisa et al. 7 also showed that adult patients with eosinophilia (eosinophil 44%) within 100 days after SCT had a higher overall survival rate (67 versus 51%, P ¼ 0.003). The authors consider that reduced severity of acute GVHD in patients developing eosinophilia leads to favorable overall survival after SCT.
We demonstrated that the incidence of eosinophilia was as high as 74.3% within 100 days after CBT. In addition, our study suggests that eosinophilia within 100 days after CBT is not significantly associated with the clinical outcome of CBT in adults; however, the genesis of eosinophilia after CBT remains uncertain. Further studies are warranted to define the significance of eosinophilia in SCT patients. Patients who survived without relapse for more than 100 days after transplantation were considered evaluable for analysis; therefore, 20 patients were excluded because of death before engraftment or the failure of donor-derived engraftment (n ¼ 10), and death or relapse after engraftment (n ¼ 10). b Low-risk diseases were defined as acute leukemia and lymphoma in the first or second CR, myelodysplastic syndrome in early phases, and CML in the first chronic phase. High-risk diseases were defined as those other than the above. c HLA-A and -B matching was confirmed by low-resolution typing methods, and HLA-DRB1 matching was confirmed by high-resolution typing methods. Severe 4.0% Figure 1 Cumulative incidence of mild-to-severe, moderate-to-severe and severe eosinophilia (absolute eosinophil count 4500, 1500 and 5000 Â 10 6 /l, respectively) at 100 days after cord blood transplantation (CBT).
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